新股消息 | 创新药企百利天恒递表港交所 2024年营收、净利大幅增长

Core Insights - Baillie Tianheng is focused on addressing unmet clinical needs in the global biopharmaceutical frontier, particularly in the field of tumor macromolecule therapy, and aims to establish comprehensive commercialization capabilities by 2029 [3][4] - The company has developed a leading innovative research and development capability in the ADC (Antibody-Drug Conjugate) sector, with a significant strategic partnership with BMS valued at $8.4 billion [3][4] Business Overview - Baillie Tianheng operates two main business segments: innovative biopharmaceuticals and generic drugs, including traditional Chinese medicine [3] - The company has established a robust ADC drug development platform, with nine ADC candidates in clinical stages and approximately 70 clinical studies conducted [4] Financial Performance - The company reported revenues of approximately RMB 7.02 billion, RMB 5.6 billion, RMB 58.21 billion, and RMB 1.7 billion for the fiscal years 2022, 2023, 2024, and the first half of 2025, respectively [4][6] - The significant revenue increase in 2024 is attributed to an $800 million upfront payment from BMS for the core product BL-B01D1 [4] - The company experienced net losses of approximately RMB 2.82 billion, RMB 7.8 billion, RMB 37.08 billion, and RMB 11.18 billion for the same periods [4][6]